Galmed Pharma (GLMD) Adds to NASH-Frenzy Gains
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
NASH stock Galmed Pharma (NASDAQ: GLMD) is pushing to the highs of the session. Shares are up 16.8% to $5.42, and up 43% since Tuesday when Allergan (NASDAQ: AGN) agreed to acquire Tobira Therapeutics (NASDAQ: TBRA) at a huge premium.
This afternoon, Galmed announced that it has signed an Investigator-Initiated Clinical Trial Agreement with the University of California, San Diego, School of Medicine.
Speculators are buying Galmed Pharma and other NASH stocks on their scarcity value and potential takeovers.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- WestRock (WRK) to Acquire Multi Packaging Solutions (MPSX) for $18 per share
- Amtech Systems (ASYS) Surges After Announcing Larger Orders
- Kellogg (K) short duration call active
Create E-mail Alert Related CategoriesMomentum Movers, Rumors, Trader Talk
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!